Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Strategy

Set Alert for Strategy

Sun’s Ilumya To Claw Into Japanese Psoriasis Market

Tildrakizumab debuts in Japan, marking a key milestone for Sun Pharma, though heavyweight competitors including same class rival Skyrizi are already available on the market there.

Immune Disorders Launches

ESMO: Merck & Co Vibostolimab Data Are Another Validation Of TIGIT

A number of anti-TIGIT drugs are jockeying for position to provide benefit as monotherapies and in combinations for non-small cell lung cancer and Merck's offering is looking to challenge Roche's tiragolumab for the lead.

ImmunoOncology Clinical Trials

Stockwatch: Can Gilead Wave Its Wand Over Antibody-Drug Conjugates?

After a slow start marked by product withdrawals and toxicity, recent deal-making activity has brought antibody-drug conjugates back from obscurity. But what has changed?

Platform Technologies M & A

Roche Pharma Chief Picks Out Pearls in Cancer Pipeline

Oncology is an area where the Swiss major has long been a dominant player, and Bill Anderson highlighted programs to Scrip which Roche hopes will help extend that dominance.

Cancer Clinical Trials

Phase II Win For Merck KGaA/Avillion Psoriasis Drug May Be Too Late

The German major is looking for a partner to advance its IL-17A/IL-17F nanobody sonelokinab for psoriasis but the search could be tricky given the strength of Novartis's Cosentyx and Eli Lilly's Taltz, while UCB's IL-17A and IL-17F inhibitor bimekizumab is likely to be approved soon.

Immune Disorders Clinical Trials

Amryt Flies As Butterfly Skin Therapy Hits Late-Stage Goal

Filsuvez has the potential to become the first treatment approved for epidermolysis bullosa, a rare genetic condition where skin can tear and blister at even the slightest touch.

Clinical Trials Rare Diseases

Sanofi Showcases Long-Term Benefits Of Dupixent For Severe Asthma

While many analysts have been focusing on the growth potential of Regeneron-partnered Dupixent in atopic dermatitis, the French giant has been highlighting the biologic's benefits for asthma with three-year data presented at the ERS meeting.

Respiratory Clinical Trials

Novartis Shows Importance Of Gene Therapy With AveXis Name Change

Novartis has completed its absorption of AveXis and rebranded the acquired gene therapy specialist that developed the soon-to-be SMA blockbuster Zolgensma despite struggling to meet the data integrity standards of regulators and big pharma.

Gene Therapy Companies

How Cipla Is Aligning Manufacturing Amid The Pandemic

Cipla senior management executive tells Scrip how the company is calibrating manufacturing as part of a wider business “reimagination” and accelerated digital adoption across its operations.

Commercial Strategy
See All
UsernamePublicRestriction

Register